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• TCR signal strength-dependent programming of CD4+ T cells revealed over 
time in vivo 
• Inhibitory receptor expression is dynamic, TCR signal strength dependent, and 
rapidly re-calibrates T cell activation thresholds 
• PD1 but not Lag3 blockade leads to a unique and increased TCR signal 
strength signature (coined TCR.strong) 
• TCR.strong metric stratifies melanoma patient survival in response to 
Nivolumab (anti-PD1) therapy 
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How T cell receptor (TCR) signal strength modulates T cell function and to what extent 
this is modified by immune checkpoint blockade (ICB) are key questions in 
immunology. Using Nr4a3-Tocky mice as a digital read-out of NFAT pathway activity, 
we identify the rapid quantitative and qualitative changes that occur in CD4+ T cells in 
response to a range of TCR signalling strengths. We demonstrate that the time and 
dose dependent programming of distinct co-inhibitory receptors rapidly re-calibrates T 
cell activation thresholds. By developing a new in vivo model, we analyse the 
immediate effects of ICB on T cell re-activation. Our findings reveal that anti-PD1 but 
not anti-Lag3 immunotherapy leads to an increased TCR signal strength. We define a 
strong TCR signal metric of five genes specifically upregulated by anti-PD1 in T cells 
(TCR.strong), which can stratify clinical outcomes during anti-PD1 monotherapy in 
melanoma patients. Our study therefore reveals how analysis of TCR signal strength 
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How T cells interpret T cell receptor (TCR) signals to promote different functional 
programmes is a critical aspect of their biology. A key feature of T cell activation is the 
release of intracellular calcium stores to trigger calcineurin-mediated activation of 
nuclear factor of activated T cells (NFAT) (Hogan et al., 2003). This process is 
proposed to occur in a digital and probabilistic fashion (Gallagher et al., 2018; 
Podtschaske et al., 2007). Similar results are reported for extracellular signal-
regulated kinase (ERK) activation (Altan-Bonnet and Germain, 2005; Das et al., 2009). 
Nonetheless, despite these digital behaviours, it is reported that TCR signal strength 
can lead to graded expression of molecules such as interferon regulatory factor 4 
(IRF4) (Conley et al., 2020), Nr4a1 (Moran et al., 2011) and co-inhibitory receptors 
(Trefzer et al., 2021). Recent data show that under reduced TCR signal strength 
levels, nuclear factor kappa B (NF-kB) activation may be analogue (Gallagher et al., 
2020). This is intriguing, as NF-kB activation plays critical roles in driving T cell 
activation, with the activity of mucosa-associated lymphoid tissue lymphoma 
translocation protein 1 (Malt1) paracaspase is key to full NF-kB activity and IL-2 
expression (Rebeaud et al., 2008).  
 
CD8+ T cell studies have reported that TCR signal strength does not influence their 
end stage cytolytic capacity in vitro (Richard et al., 2018). However, analysis of thymic 
CD4+ T cell development clearly demonstrates that strong and persistent TCR signals 
drive Foxp3+ Treg development (Bending et al., 2018b; Jennings et al., 2020; Moran 
et al., 2011), and antigen affinity and dose have distinct effects on peripheral CD4+ T 
cell transcriptional programmes (Keck et al., 2014; Trefzer et al., 2021). Understanding 
how graded responses to TCR signal strength can modulate T cell function is likely to 
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be critical to understanding mechanisms behind immunotherapies. For example, key 
T cell transcripts may require differing thresholds of TCR signal strength, meaning 
some are more amenable to manipulation through immune checkpoint blockade 
(Shimizu et al., 2020). 
 
Whilst many studies have sought to investigate TCR signalling using in vitro systems, 
the study of how TCR signal strength temporally regulates T cell activation and how 
immunotherapy may alter these processes are far from clear. In particular, antigen 
levels can influence the rates of T cell activation, meaning that in vivo studies may 
struggle to dissect differences that occur due to differing T cell activation kinetics 
(Richard et al., 2018). Furthermore, different T cell genes may require differing 
durations of TCR signals for expression (Jennings et al., 2020). 
 
To address the challenges of studying T cell activation dynamics, we previously 
developed the Nr4a3-Timer of cell kinetics and activity (Tocky) model (Bending et al., 
2018b). Nr4a3-Tocky mice are NFAT-responsive distal TCR signalling reporter mice 
(Jennings et al., 2020; Jennings et al., 2021), that exhibit reduced background 
expression compared to other TCR signalling reporters. Nr4a3-Tocky utilises a 
fluorescent timer protein (Subach et al., 2009) to monitor the temporal dynamics of 
TCR signalling and can classify TCR signals according to whether they are new, 
persistent, or arrested. Importantly, given that NFAT is necessary and sufficient for 
expression of Nr4a3 in T cells (Jennings et al., 2020; Martinez et al., 2015), we 
predicted that Nr4a3 would represent a digital read-out for T cell activation in vivo, 
which would permit the tracking of T cells following antigen encounter over the first 24 
hours. Here we employ the Tg4 Nr4a3-Tocky (Jennings et al., 2020) mouse model to 
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track synchronised T cell activation in vivo, and identify quantitative and qualitative 
changes that occur in T cells receiving different strengths of TCR signalling in vivo. 
Importantly this system accounts for differing proportions of T cells that may respond 
whilst also permitting the analysis of T cells at different synchronised phases following 
T cell activation. Our findings identify the relationships between TCR signal strength 
and key T cell transcriptional programmes, including the programming of temporally 
distinct co-inhibitory receptor modules. These modules rapidly re-calibrate the 
activation threshold of T cells, allowing direct detection of the immediate effects of 
immune checkpoint blockade on the re-activation of T cells in vivo. Our findings reveal 
that anti-PD1 but not anti-Lag3 immunotherapy leads to an increased TCR signal 
strength signature. We refine a TCR signal strength metric down to 5 genes 
specifically upregulated by anti-PD1 in T cells (called TCR.strong), which stratifies 
clinical outcomes following anti-PD1 monotherapy in melanoma patients. 
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Antigen dose drives digital Nr4a3 activation at the single cell level but graded 
responses at population and phenotypic levels 
To investigate the regulation of T cell activation, we utilised the Nr4a3-Tocky system, 
which is an NFAT-dependent distal TCR signal reporter (Jennings et al., 2020) 
crossed with the Tg4 TCR transgenic line that recognises myelin basic protein (MBP) 
peptide (Figure 1A). This system has been useful in assessing the response of T cells 
to modified self-antigens, and it is known that repeated dosing of this system imparts 
a Type 1 regulatory (Tr1) phenotype (Burton et al., 2014)  supported by epigenetic 
remodelling (Bevington et al., 2020). Therefore, to monitor changes in IL-10 
expression our model also incorporated an IL-10-IRES-GFP reporter (Kamanaka et 
al., 2006). In vitro experiments demonstrated that activation with the native lysine at 
position 4 [4K] MBP peptide induced weak activation of Tg4 T cells (Supplementary 
Figure 1A&B). Through switching of the fourth peptide residue to alanine [4A] or 
tyrosine [4Y], the potency of TCR signalling increased significantly (Supplementary 
Figure 1A&B).  
 
To determine how TCR signal strength affects NFAT/Nr4a3 activation in vivo, a 
hundred-fold range of [4Y] MBP peptide was administered to Tg4 Nr4a3-Tocky IL-10-
GFP mice, and Nr4a3 expression monitored over the first 24 h period (Figure 1B-D). 
As expected at 4 h, splenic T cells responded with an increase in Nr4a3-Blue 
expression, indicating new TCR signalling in response to recognition of the [4Y] MBP 
peptide. By 12 h, a population of CD4+ T cells had become Nr4a3-Blue+Red+, 
indicating the increased time elapsed since initiation of TCR signalling. Strikingly, by 
16-24 h responding T cells had migrated towards the arrested Nr4a3-Timer locus 
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(Figure 1B) (Bending et al., 2018b). This indicated that the majority of T cells 
experiencing stimulation in this in vivo model arrest Nr4a3 expression within the first 
24 h. Analysis of active TCR signalling showed a peak at 4 h, before a fall to near-
zero by 24 h (Figure 1C). These results show that the proportion of responding T cells 
was dependent on TCR signal strength. However, analysis of Nr4a3-Timer Angle 
(which determines the average position of Nr4a3-Timer+ T cells in Blue-Red space, 
(Bending et al., 2018b)) showed highly similar Timer trajectories independent of the 
immunising dose (Figure 1D). Therefore, the strength of TCR signalling did not affect 
the dynamics of Nr4a3 activation; moreover, at the single cell level those T cells that 
crossed the threshold of activation of the NFAT/Nr4a3 pathway exhibited highly similar 
dynamics of Nr4a3 expression. However, in the 24 h stimulation period, early 
expression of IL-10-GFP emerged within Nr4a3-Timer+ T cells with a direct correlation 
to the amount of immunising antigen (Figure 1E-F), reflecting that TCR signal strength 
can impart rapid phenotypic heterogeneity within activated Nr4a3+ T cell populations 
in vivo.  
 
CD4+ T cells rapidly discriminate stimulation strength through transcriptionally 
distinct and time-dependent activation profiles 
The previous data support that the Tg4 Nr4a3-Tocky system can be used to study the 
temporal dynamics of T cell activation and differentiation during the first 24 h in vivo. 
Based on the link between IL-10 GFP and TCR signal strength, we hypothesised that 
signal strength imparts both quantitative and qualitative changes, specifically that the 
TCR signal strength controls the proportion of activated T cells and phenotypically 
distinct activation profiles. We repeated in vivo subcutaneous immunisations of Nr4a3-
Timer Tg4 Tiger mice with [4Y] MBP peptide at a 100-fold dose range (0.8 μg and 80 
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μg) (Figure 2A). In order to control for quantitative differences between the two 
conditions and identify purely qualitative responses to signal strength, we sorted cells 
based on their Timer protein maturation profile (4 h Blue+Red- new signalling, 12 h 
Blue+Red+ persistent signalling, 24 h Blue-Red+ arrested signalling). This allowed us 
to isolate T cell populations from different conditions at highly synchronised stages of 
TCR signalling trajectory, as a comparable period of time had elapsed since the signal 
threshold for Nr4a3 expression was met. RNA was extracted from sorted cells and 3’ 
mRNA libraries were prepared for RNA sequencing. Principal component analysis 
(PCA) revealed four clusters indicating the control, 4 h, 12 h and 24 h immunised 
groups (Figure 2B). Within each time cluster, they separated into two distinct groups 
based on the level of immunising antigen. We decided to focus our analysis on 
differentially expressed genes (DEGs) between the low and high immunising groups 
at each time point identified using the DESeq2 algorithm (Love et al., 2014)(Figure 
2C, Supplementary Table 1). Our analysis revealed that the highest number of DEGs 
were present at the 4 h time period, which declined in a time dependent fashion. 
Analysing the overlap of genes upregulated or downregulated at the different time 
points suggested that the majority of these genes were unique to the time point of 
analysis (Figure 2D). Heatmap analysis of the cumulative DEGs across the 3 time 
points revealed that 24 h samples clustered tightly with the non-activated control 
population (Supplementary Figure 2A), with 4 h and 12 h clusters separating into 
discrete branches. To understand biological processes that are influenced by TCR 
signal strength, we performed Kyoto encyclopaedia of genes and genomes (KEGG) 
pathway analysis on 4 and 12 h DEGs (Figure 2E-F, Supplementary Table 2). Notable 
pathways showing significant enrichment at 4 h included, cytokine-cytokine receptor 
interactions, JAK-STAT signalling, Th17 cell differentiation, Th1 and Th2 cell 
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differentiation and TCR signalling pathways. Interestingly, several of these pathways 
were still enriched at 12 h (Figure 2F). Analysis of 24 h DEGs reflected sustained 
changes in cytokine-cytokine receptor interactions and JAK-STAT signalling 
(Supplementary Figure 2B). Based on these findings, we conceptualised 7 key 
modules that were undergoing time and dose-dependent transcriptional activation or 
suppression (Figure 2G). 1) A shared activation module, incorporating the Nr4a1-3 
receptors, which exhibited rapid induction at 4 h, and was largely off by 12 h. Cd69 
and Tnf expression were also tightly linked to this group. 2) A second group of 
activated genes which trended to have higher and/or longer expression, including TNF 
superfamily costimulatory receptors Tnfrsf4 (OX40), Cd40lg, the inhibitory receptor 
Pdcd1 (PD1), and IL-2 signalling (Il2 and Il2ra). Included here was Irf4 (previously 
reported to be graded in response to TCR signalling (Conley et al., 2020)), Irf8 and 
Tbx21 (T-bet). 3) A third module incorporating Th1 associated/ T cell effector functions 
(Ifng, Il12rb2, Gzmb), which exhibited rapid induction at 4 h in the 80 μg antigen group. 
Interestingly this module showed delayed activation in the 0.8 μg group; however, 
Gzmb and Il12rb2 remained high and sustained throughout the 24 h period in 80 μg 
group. 4) A fourth module specific to strong TCR signalling was upregulated at 4 and 
12 h, and largely sustained at 24 h. This included the Th17-associated genes Rora, 
Rorc, and Il21. In addition, Malt1, an enzyme involved in NF-kB signalling (a pathway 
that is linked to graded responses to TCR signal strength (Gallagher et al., 2020)) was 
strongly induced at 4 h and 12 h in 80 μg stimulated group along with the Mt1 and Mt2 
enzymes involved in zinc bioavailability. 5) The fifth module involved genes 
undergoing strong and sustained expression that was largely specific to high antigen 
dose. These included Ctla4, Icos and Maf. 6) The sixth module identified a delayed 
and negative regulatory motif which appeared transiently at the 12 h time point in the 
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80 μg group. This module included Il10 (echoing the findings in Figure 1E), Lag3, Nfil3 
and Tigit which are all associated with Tr1 cells. Interestingly this module peaked after 
the termination of TCR signalling (as evidenced by Nr4a1-3 expression dynamics) in 
the 80 μg immunised group. A final module exhibited strong but transient 
downregulation of key parts of the TCR signalling pathway (Cd3g, Cd3e, Lck, 
Rasgrp1) at the 4 h period in the high antigen dose group, indicating negative feedback 
responses to high antigen dose are stronger in this group in vivo; however, by 24 h 
the expression of these genes had returned to baseline levels. Included in this group 
was also the Th2-associated transcription factor Gata3 that was strongly 
downregulated at 4 h and 12 h, reflecting the KEGG pathway analysis of T cells 
inducing signatures of Th1 and Th17 programmes (Rora, Rorc, Tbx21, Ifng, Il12rb2, 
Il21). Analysis of DEGs across all time points, revealed that Il21, Il12rb2, Tbx21, Maf 
and Malt1 were sustained across the whole 24 h period, indicating a motif strongly 
associated with T cells experiencing a very strong TCR signal in vivo (Supplementary 
Figure 2C). In summary, our analysis identified clear signatures of diverse 
transcriptional programmes being induced in a time and dose-dependent fashion in 
vivo. These data suggest that, perhaps dissimilarly to reports for CD8+ T cells (Richard 
et al., 2018), early CD4+ T cell differentiation fates display greater tunability to antigen 
levels, and exhibit hallmarks of multiple T helper and T regulatory lineages. 
 
Nr4a3 activation threshold is calibrated by dose dependent negative feedback 
A key finding from the time-dependent analysis of transcriptional programmes from T 
cells activated in vivo was the relationship between key negative regulators and TCR 
signal strength (Figure 3A). PD1 for instance was tightly coupled to T cell activation 
(Supplementary Figure 3A) and only modestly influenced by TCR signal strength; 
CTLA-4 (Supplementary Figure 3B) was very much dependent on the immunising 
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dose, and differences in expression were detectable within 4 h. Interestingly the Tr1-
associated module exhibited delayed and transient induction in response to strong 
TCR signalling (Lag3, Tigit and IL10, Supplementary Figure 2D and Figure 1E-F). 
Given this upregulation of multiple immune checkpoints and/or immunoregulatory 
cytokines we hypothesised that T cell responsiveness to acute re-stimulation would 
be dependent on the immunising dose. Moreover, we hypothesised that the T cells 
that arrested TCR signalling in response to weak TCR signalling would be more 
sensitive to restimulation than T cells initially activated with a strong TCR signal 
(Figure 3B). Given that Tg4 Nr4a3-Tocky T cells activated with peptide for 24 h move 
into the Blue-Red+ quadrant, due to arrested TCR signalling (Figure 1B-D), 
rechallenge with peptide at this time point would lead to the re-emergence of Nr4a3-
Blue expression in this population (Figure 3B), and move up into the Blue+Red+ 
quadrant. If the re-challenge duration is restricted to 4 h (Figure 3B), then almost all 
Nr4a3-Blue+Red+ T cells will represent T cells that are responding to the first and 
second stimulations. This is possible due to the fact that the half-life of Nr4a3-Blue 
protein is 4 h whilst Nr4a3-Red is 120 h (Bending et al., 2018a). T cells that remain in 
the lower right quadrant (Nr4a3-Red+Blue-) even after re-stimulation would reflect T 
cells that fail to re-activate in response to the second dose. To test this hypothesis, we 
immunised mice with either 0, 8 or 80 μg of [4Y] MBP peptide to induce no, moderate 
or strong TCR stimulation. 24 h later, we sub-divided these three groups into two 
groups to receive a further 8 or 80 μg stimulation for 4 h to trigger Nr4a3-Blue 
expression. Our analysis focused on assessing the proportion of T cells that remained 
within the arrested TCR signalling quadrant (i.e., Nr4a3-Blue-Red+). Administration of 
0 μg followed by 8 μg or 80 μg induced as expected cells predominantly in the new 
Timer locus (Figure 3C, left). Immunising with an initial 8 μg and then rechallenge with 
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8 μg or 80 μg induced a clear Nr4a3-Blue+Red+ indicating that the majority of these 
previously activated T cells responded to the second dose (Figure 3C, middle). In 
contrast, most T cells immunised with 80 μg and challenged with 8 μg remained in the 
arrested Timer locus (Figure 3C, right). Even when re-stimulating with 80 μg, a 
significant proportion of arrested TCR signalling cells remained. Summary analysis 
revealed that significantly more T cells failed to re-activate Nr4a3 expression in 
response to a second restimulation with 8 μg or 80 μg when the T cells had been first 
immunised with 80 μg (Figure 3D). Importantly this defect was not linked to any 
differences in the levels of TCR or CD4 (Figure 3E). In summary, our data reveal that 
T cell activation thresholds are recalibrated by the initial TCR signalling episode in 
vivo. 
 
Co-inhibitory receptors exert distinct quantitative and qualitative control over T 
cell re-activation 
Exposure of self-reactive T cells to a high dose of modified self-antigen led to reduced 
responsivity to further stimulation and this was correlated with high levels of immune 
checkpoint receptor expression. We therefore explored the extent to which different 
checkpoints can modulate the thresholds for re-activation of T cells in vivo. We chose 
PD1, CTLA4/CD28 and Lag3 pathways to compare checkpoints from three modules 
identified in Figure 3A. We adapted the model from Figure 3B, to include 
administration of a blocking antibody to the co-inhibitory receptor 30 minutes before 
the 4 h rechallenge with [4Y] MBP peptide (Figure 4A). In this way we could gain novel 
insights into the immediate effects of co-inhibitory receptor blockade on the T cell re-
activation process in vivo. Experiments administering an agonistic CD28 antibody (to 
bypass potential effects of high CTLA4) did not alter the threshold for activation of T 
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cells in this model (Supplementary Figure 4A&B), we therefore focused our exploration 
on the potential roles Lag3 and PD1 play in modulating T cell re-activation (Figure 4B). 
Anti-PD1 blockade induced a significant increase in responders (Figure 4B-D), with 
anti-Lag3 inducing an intermediate effect on the re-activation of T cells. Interestingly 
anti-PD1 induced higher levels of Nr4a3-Blue in responding T cells (Figure 4D), than 
mediated by the isotype pool group or anti-Lag3. These data support that PD1, and to 
a lesser extent Lag3, quantitatively control the activation thresholds of T cells in vivo 
as reported by NFAT/Nr4a3 activity. 
 
As anti-PD1 induced higher levels of Nr4a3-Blue, we hypothesised that anti-PD1 may 
also induce qualitative changes within T cells re-activating in the presence of its 
blockade. The precise signalling mechanism of PD1 in an in vivo environment is still 
unclear, with recent in vitro studies suggesting that it may preferentially target the 
CD28 co-stimulatory pathway (Hui et al., 2017). Our data presented here provide 
evidence that it can also lower the threshold for the NFAT/Nr4a3 pathway on 
previously activated T cells. In order to compare T cells responding to ICB in vivo, we 
isolated Nr4a3-Blue+Red+ responder T cells from Isotype, anti-Lag3 or anti-PD1 
treated mice (Figure 4E). As before, we isolated Nr4a3-Blue+Red+ to control for 
differences in the proportions of responding T cells. This experiment once again re-
capitulated the quantitative effects of PD1 and Lag3 blockade on the frequency of 
responding cells (Supplementary Figure 4C-E). RNA was extracted from these sorted 
T cells and subjected to 3’ mRNA sequencing. PCA analysis showed that anti-PD1 T 
cells clustered as a separate group to the isotype and anti-Lag3 groups (Figure 4F). 
DESeq2 analysis revealed that 69 DEGs existed between the anti-PD1 and Isotype 
group, demonstrating that 4 h of T cell activation in the presence of anti-PD1 is 
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sufficient to impart qualitative changes within responding T cell populations 
(Supplementary Table 3). KEGG pathway analysis revealed signatures very similar to 
those observed in the strong TCR signalling analysis in Figure 2E-F. Cytokine-
cytokine receptor, JAK-STAT, Th1/Th2/Th17 differentiation, TCR signalling and PD-
L1 expression and PD-1 checkpoint pathway in cancer were significantly enriched 
terms (Figure 4G). Heatmap analysis showed anti-PD1 clustered distinct from Isotype 
or anti-Lag3 groups (Figure 4H). Notably we saw an enrichment of costimulatory 
receptors, including Tnfrsf4, Tnfrsf9, Tnfrsf18 and Icos. In addition to Irf4 and Irf8, as 
with 80 μg versus 0.8 μg primary TCR stimulation (Figure 2). Strikingly, Il21, Il12rb2 
and Malt1 were also upregulated in anti-PD1 treated T cells (as had been indicated as 
sustained markers in Figure 2G). Given the striking similarity between the genes 
upregulated in the anti-PD1 group compared to controls and those identified in T cells 
stimulated for 4 h with a high antigen dose we compared the intersect of the DEGs 
between the two mRNA-seq experiments (Supplementary Figure 5). Our analysis 
showed that 28/51 of the genes upregulated in T cells re-activated in the presence of 
anti-PD1 were also genes upregulated in T cells experiencing a strong initial TCR 
signal for four hours. These data support the notion that anti-PD1 not only increases 
the probability of a T cell re-activating NFAT/Nr4a3 due to lowering the threshold of 
activation, but also results in a qualitatively stronger TCR signal, which is not evident 
in response to anti-Lag3 blockade. 
 
Strong TCR signalling signatures in tumours of anti-PDL1 treated mice  
In order to investigate the relevance of our T cell gene signatures further, we utilised 
the MC38 colorectal cell line model. This model responds to anti-PDL1 therapy 
(Efremova et al., 2018), enabling us to explore transcriptional changes occurring in 
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tumours in a polyclonal T cell setting. We injected MC38 tumour cells into the flanks 
of Nr4a3-Tocky IFNg-YFP mice, to examine the dynamics of tumour development and 
T cell responses. Tumours increased in weight and volume from day 7 to day 14 
(Figure 5A). At days 7, 11 and 14, CD8+ TILs were analysed for Nr4a3-Timer, PD1, 
Lag3 and IFNg expression (Figure 5B-E). The frequency of Nr4a3-Timer+ T cells 
increased over time, as did the development of arrested Nr4a3-Timer-Blue-Red+ T 
cells (Figure 5C). This was accompanied by a time dependent upregulation in the 
checkpoints PD1 and Lag3, with approximately 50% of T cells PD1+ at day 7, rising to 
90% by Day 14 (Figure 5D). A time-dependent increase in IFNg expression was also 
detected, and increasingly the IFNg-YFP+ T cells co-expressed Nr4a3-Timer, 
indicating that these were recently activated CD8+ T cells within the tumour 
microenvironment (Figure 5E). This confirmed that the MC38 model exhibits hallmarks 
of chronically stimulated CD8+ T cell responses and would serve as a useful model for 
investigating T cell signatures of response to immune checkpoint blockade. We 
analysed a previously published 3’ mRNA sequencing dataset performed in mice 
transplanted with MC38 tumours that were subsequently treated with anti-PDL1 or 
isotype control (Efremova et al., 2018). We identified 357 genes that were upregulated 
(>1.5-fold, adjusted p value<0.05) in the dataset, and heatmap analysis showed strong 
signatures in 2 out of 3 anti-PDL1 treated mice, with an intermediate signature in the 
third anti-PDL1 treated mouse (Figure 5F). We interrogated the genes identified from 
our analyses in Supplementary Figure 5 (Upregulated in both 80 μg vs 0.8 μg and anti-
PD1 vs Isotype datasets), to visualise expression of these genes in the Efremova et 
al. dataset (Figure 5G, 25 out of 28 detected). These data demonstrated that the 
majority of signature T cell genes identified in Figure 5 were upregulated (or trended 
to be upregulated) within the anti-PDL1 treatment group in this model, including 
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Tnfrsf4, Icos, Irf8, Chmp4b and Irf4. This suggests that our T cell signatures identified 
through the Tg4 Nr4a3-Tocky model are faithful at discriminating T cell responses in 
an anti-PDL1-responsive tumour model. 
 
Identification of a strong TCR signal metric that stratifies melanoma patient 
responses to nivolumab therapy 
Our findings that anti-PD1 imparts unique signatures of strong TCR signalling led us 
to hypothesise that genes upregulated in response to strong TCR signalling (Figure 2) 
or genes upregulated in T cells reactivated in presence of anti-PD1 (Figure 4) could 
be useful for identifying T cell intrinsic correlates of cancer patients responding to PD1 
immunotherapy. We analysed a human gene expression dataset of biopsies from 
advanced melanoma patients before and after nivolumab therapy. DEGs were 
examined in those on therapy (OT, DEGs Between Pre- and On-therapy Samples, 
Regardless of Response) or in those with evidence of clinical response (Res= DEGs 
Between Pre- and On-therapy samples, considering genes that change differentially 
in Responders versus Non-responders) ((Riaz et al., 2017) CA209-038 study). We 
intersected these genes with DEGs from our Tg4 Nr4a3-Tocky datasets: 4 h T cells 
stimulated with 80 μg vs 0.8 μg (called Strong 4hr) and DEGs in T cells re-activated 
for 4 h in the presence of anti-PD1 vs isotype (PD1). Almost all genes in the on-therapy 
group were also found within the DEGs in those who exhibited signs of clinical 
response (Figure 6A, Supplementary Table 4). We identified 5 gene groups of interest 
intersecting between responders and 4 h/ anti-PD1 (or both). Interestingly, intersection 
of 4 h and anti-PD1 datasets showed that 2 genes, ICOS and TNIP3, were associated 
with both anti-PD1 and strong TCR signalling in mice as well as clinical response to 
nivolumab, although these genes also changed in patients on therapy regardless of 
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response (group I). This indicates that these may be pharmacodynamic correlates of 
anti-PD1 therapy. TNFRSF4 (OX40), IRF8 and STAT4 genes were uniquely 
upregulated only in patients who clinically responded to nivolumab, and also were 
predicted from our strong 4 h TCR and murine anti-PD1-specific T cell signatures 
(Figure 6A, group II). This suggests that these transcripts may act as genetic 
biomarkers of an effective anti-cancer T cell response to therapy. Genes such as 
IFNG, GZMB (T cell effector cytokines) and CTLA4 (checkpoint) were upregulated in 
the 4 h strong TCR signalling group but also in both the clinical responders and on 
therapy groups, suggesting that these also show pharmacodynamic responses (group 
III). Further analysis between clinical response and strong TCR signalling in murine T 
cells showed that genes associated with immune regulation (IL2RA, IL10) were 
significantly upregulated in T cells exhibiting strong TCR signals and only in those 
patients with objective responses to nivolumab (group IV). Furthermore, we identified 
CD5, GPR65 and GCNT1 as a motif that is upregulated on T cells in response to anti-
PD1 blockade in mice as well as only in melanoma patients who respond to nivolumab 
(group V). 
 
Based on these findings, we selected genes in group I (ICOS, TNIP3) and group II 
(TNFRSF4, IRF8, STAT4) as the basis for creating a transcriptional signature metric 
for strong TCR signalling (TCR.strong). We reckoned that by combining indicators of 
T cell pharmacodynamic responses to anti-PD1 (ICOS, TNIP3), with genes uniquely 
changing in patients showing clinical benefit that are also associated with strong TCR 
signalling and anti-PD1-specific T cell changes (TNFRSF4, IRF8, STAT4) we could 
develop a metric to stratify patient responses to therapy. We utilised an analogous 
approach to that taken for the Cytolytic score metric, where the geometric mean is 
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taken for the transcripts per million (TPM) from sequencing data (Rooney et al., 2015). 
Using our TCR.strong metric, we interrogated the dataset for nivolumab patients 
based on their responses and ipilimumab status (Supplementary Table 5). We 
followed the characterisation of (Riaz et al., 2017), who characterised responding 
patients (or patient benefit) as those showing complete response, partial response or 
stable disease. Non-responders (or no-benefit) were classified as those with 
progressive disease. We divided patients into ipilimumab progressed or naïve, and 
analysis of the TCR.strong metric in pre-nivolumab biopsies showed no significant 
differences between responder and non-responders in either ipilimumab progressed 
or naïve groups (Figure 6B). Analysing biopsies from patients on therapy revealed a 
strong increase in the metric for the ipilimumab naive cohort in patients with clinical 
responses (p=0.0069), and a clear but not significant trend in patients who were 
ipilimumab progressed (p=0.1710, Figure 6C).  
 
To determine the change in the TCR.strong metric before and after therapy, we 
identified all patients with pre and on therapy biopsies who had known clinical 
outcomes (Figure 6D-E, Supplementary Table 5). In both the ipilimumab progressed 
and naïve cohorts, non-responders had no change in their TCR.strong metric, 
suggesting that the TCR.strong metric is not influenced by anti-PD1 
pharmacodynamics. However, ipilimumab progressed patients with clinical responses 
displayed a small but significant increase (p=0.0394) in their TCR.strong metric 
(Figure 6D) from pre-therapy levels. For the ipilimumab naïve cohort this increase was 
more striking and statistically very significant (p=0.00099) in those with evidence of 
clinical benefit. These differences were clearly illustrated by heatmap analysis of the 
log2 transformed expression of the 5 genes, showing a stronger and more consistent 
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pattern in the ipilimumab naïve group (Figure 6F) compared to ipilimumab progressed 
patients (Figure 6G). By using a TCR.strong score threshold of 3.5, we divided patients 
into TCR.strong high and TCR.strong low groups (Figure 6H-I). Based on this, survival 
curve analysis showed that high pre-therapy TCR.strong scores had no predictive 
power in either cohort. In contrast, large survival benefits were found in patients on-
therapy with high TCR.strong scores within the cohort of ipilimumab naïve patients 
(median survival 142 weeks versus 36.6 weeks, p=0.00018). Interestingly, no 
difference was observed in the ipilimumab progressed groups, suggesting that the 
mechanism of action of anti-PD1 differs in patients pre-treated with anti-CTLA4. Taken 
together these data highlight how insights from murine models into transcriptional 
programmes induced either by strong TCR signalling or PD1 blockade during T cell 
re-activation can identify TCR signalling based metrics to identify signatures of 
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In this study we sought to understand how antigen levels and immune checkpoints 
modulate the strength of TCR signalling and the early T cell activation process in vivo. 
As the frequency of a given TCR precursor in a polyclonal setting influences its 
magnitude of response to an antigen (Moon et al., 2007) we took a reductionist, TCR 
transgenic approach to focus solely on T cells within the same clonal niche. Through 
manipulating T cell responses to a modified self-antigen, we identified basic 
immunological mechanisms that drive the re-calibration of T cell activation thresholds 
and refine a TCR signal strength metric that can monitor melanoma patient responses 
to nivolumab. 
 
The use of a highly soluble peptide (Ac-[4Y]-MBP) in the Tg4 TCR transgenic model 
allowed us to make robust analyses of systemic T cell responses, as our model leads 
to the rapid and synchronised activation of T cells. This meant we were able to follow 
the activation trajectories, due to maturation of Nr4a3-Timer protein, of peripheral T 
cells experiencing different strengths of TCR signalling in vivo. Our findings identified 
several facets of T cell activation that appear to be rapidly programmable due to the 
strength of TCR signals experienced. We provide evidence that strong TCR signalling 
leads to the early upregulation of multiple T helper pathways within the same clonal 
niche, with a bias toward pathways associated with Th1 (Tbx21, Irf4, Il12rb2, Stat4, 
and repressed Gata3), Th17 (Rorc, Rora, Il21), and Tr1 cells (Maf, Nfil3, Lag3, Il10). 
Whilst these findings echo the concept that Th1 cell development depends on the 
strength of TCR signals compared to Th2 (Constant et al., 1995), multiple studies have 
identified that TCR signal strength plays a key role in directing CD4+ T cell 
differentiation (Tubo and Jenkins, 2014). Our data, however, suggest that great 
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heterogeneity exists in the early T cell response that does not fit to a simplified model 
of T helper cell differentiation. These findings echo recent reports of gut CD4+ T cell 
programmes displaying a continuum of phenotypes (Kiner et al., 2021).  
 
Our approach allowed us to only compare T cells that had very recently activated the 
NFAT/Nr4a3 pathway in vivo (Jennings et al., 2020), allowing us to control for the 
relative frequency of responders whilst also comparing them at similar phases 
following TCR ligation. This approach also allowed us to interpret the kinetics of the 
activation of key T cell modules. Interestingly, Gzmb and Ifng, which are hallmark 
genes of CD8+ T cell responses, were primed in both weak and strong TCR signalling 
conditions but with differing kinetics. These data suggest that, within T cells that cross 
the NFAT/Nr4a3 activation threshold, some modules are primed regardless of the 
TCR signal strength, a finding shown clearly for CD8+ T cells and their cytolytic 
capacity in vitro (Richard et al., 2018). However, our findings also reflect that the speed 
and duration with which these modules are activated differ, with evidence of sustained 
activation in T cells experiencing a strong TCR signal. In addition, some unique 
signatures of strong TCR signalling were evident – including the Th17-associated 
programme (Rora, Rorc, Il21), enzymes involved in zinc bioavailability (Mt1, Mt2, 
linked to T cell exhaustion (Singer et al., 2016)), and sustained activation of Malt1. 
Malt1 has essential roles in NF-kB activation in T cells (Rebeaud et al., 2008), and it 
is tempting to speculate that its function is important in switching NF-kB to full and 
binary activation that is not achieved by less potent TCR ligands (Gallagher et al., 
2020). 
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Our approach also permitted us to have an in-depth analysis of negative regulators of 
the T cell activation process, including determining the relationships between key 
immune checkpoints and the strength and duration of TCR signals. It has been 
proposed previously that self-peptide/MHC abundance may tune the responses of T 
cells to antigen (Grossman and Paul, 2015), as shown that those with higher levels of 
Nur77 and CD5 exhibit hall marks of T cell anergy (such as PD1 and Cbl expression 
(Zinzow-Kramer et al., 2019)). Our approach reveals how TCR signal strength primes 
key immune checkpoints with relevance to immunotherapy. Notably CTLA-4 was 
heavily influenced by the strength of TCR signalling, giving a graded response to 
antigen dose in vivo. In contrast, PD1 showed only a very modest reduction in 
response to weaker TCR signals, highlighting that PD1 is tightly linked to the activation 
process. Intriguingly Lag3, Tigit and IL-10, appeared as a delayed and transient 
module, largely unique to stronger TCR signalling groups. Similar observations have 
been observed in chronic tolerance models (Burton et al., 2014) and in models of 
persisting antigen (Trefzer et al., 2021). 
 
Our findings reveal that very strong TCR signalling leads to a rapid re-calibration of T 
cell activation thresholds at 24 h. We believe this is not due to negative feedback 
regulation of the TCR signalosome (as CD4 and TCR complexes rapidly recover to 
control levels by 24 h), but a re-wired T cell activation state akin to adaptive tolerance 
(Chiodetti et al., 2006). Furthermore, this state is dynamic since it can be overcome 
by increasing the TCR signal strength through increasing the amount of antigen or 
through the blockade of negative regulators such as PD1 and Lag3. This tuneable 
activation threshold allowed us to directly compare the potencies of PD1 and Lag3 in 
controlling the early re-activation of T cells in vivo. Our data clearly show that both 
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exert quantitative control on the frequencies of re-activating T cells; however anti-PD1 
showed clear qualitative in vivo effects, echoing some recent in vitro studies (Shimizu 
et al., 2020). Other recent data have suggested that Lag3 has a complex mechanism 
of action but it is likely that it at least in part functions through administering inhibitory 
signals (Maruhashi et al., 2018). Our data support a weak role in controlling 
NFAT/Nr4a3 pathway activation, with no evidence that it alters the quality of the 
resulting TCR signal. This is in contrast to PD1, which imparted features of strong TCR 
signalling on re-activating T cells. Interestingly the unique signature of T cells re-
activated in the presence of anti-PD1 re-capitulated many pathways seen in earlier 
analyses comparing weak and strong TCR signalling. Once again, a bias towards Th1 
and Th17-type pathways was evident, and the strong TCR signalling motif of Il21, 
Malt1, Il12rb2, Irf4, Irf8, Tnfrsf4, Tnfrsf18 and Icos was readily detectable. In fact, 
28/51 genes identified in these analyses overlapped with genes upregulated by strong 
TCR signals. This finding is intriguing given that anti-PD1 has been proposed to target 
the anti-CD28 co-stimulatory pathway (Hui et al., 2017). In our study, CD28 agonism 
had no effect on T cell re-activation, suggesting that anti-PD1 also directly functions 
to target the TCR driven NFAT/Nr4a3 pathway in vivo. 
 
Given the transcriptional features of T cells reactivating in the presence of anti-PD1 
we interrogated to what extent strong TCR signatures are evident in human datasets 
of melanoma patients undergoing nivolumab therapy (Riaz et al., 2017). This dataset 
is particularly powerful as it permits us to compare genes that change on therapy with 
those that change in only patients who significantly respond, thereby highlighting 
potential biomarkers to monitor anti-PD1 responses. It has been clearly documented 
that IFNg signatures are a key part of the anti-PD1 response (Grasso et al., 2020; Riaz 
et al., 2017). In addition, many T cell signatures have been reported to be predictive 
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for anti-PD1 response in a variety of tumour types, including cytolytic (Rooney et al., 
2015), T cell IFNg-related mRNA profiles (Ayers et al., 2017), the chemokine CXCL9 
(Chow et al., 2019; House et al., 2020; Litchfield et al., 2021), CD8A (Tumeh et al., 
2014) and an antagonistic inflammatory phenotype (Bonavita et al., 2020). A large 
recent meta-analysis concluded that a compound signature involving tumour 
mutational burden, CXCL9, UV, APOBEC and tobacco signatures can identify pan-
cancer responses to ICB (Litchfield et al., 2021). Identification of biomarkers of ICB 
efficacy before treatment commences would be ideal, as patients could be given 
treatment based on the likelihood that they will respond. However, given that the 
majority of patients do not respond to ICB (Borcoman et al., 2019; Sharma et al., 
2017), ethically such a test would need to have a very high positive predictive value 
for widespread clinical application in order to avoid the potential denial of patients of 
life-extending treatments. Our analysis shows that hallmark signatures of strong TCR 
signalling or signatures imparted in T cells re-activating in the presence of anti-PD1 
can stratify the outcomes of patients on nivolumab therapy. Our TCR.strong metric 
comprised of 5 immunological genes (TNFRSF4, IRF8, STAT4, TNIP3, ICOS – the 
latter previously identified as a potential marker for T cell mediated response to anti-
PD1 monotherapy in melanoma, (Xiao et al., 2020)) that were indicated to be genes 
upregulated rapidly in T cells (<4 h) either experiencing a primary strong TCR signal 
or in T cells re-activated in the presence of anti-PD1. Importantly the TCR.strong 
metric was not altered in patients without clinical response, suggesting that these 
genes are less sensitive to potential pharmacodynamic effects of anti-PD1 therapy. It 
also demonstrates that this metric cannot predict patient responses before the onset 
of therapy. However, there remains an urgent need to identify markers to monitor 
treatment efficacy in patients, in order to inform clinical decision making and enhance 
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the implementation of precision immunotherapy (Havel et al., 2019). In addition, we 
anticipate that as increasing numbers of ICB combinations become available, 
identifying signatures for treatment monitoring for efficaciousness will become 
increasingly as important as identifying predictive biomarkers.  
 
Intriguingly, the TCR.strong metric was most increased in ipilimumab naïve patients 
and this was reflected in its significant correlation with overall survival in this patient 
cohort. In fact, it was striking that all patients with low TCR.strong scores died within 
the ipilimumab naïve cohort, compared to 50% survival in the patients with high 
TCR.strong scores. These data support the conclusion that strengthened and/or 
sustained TCR signalling in the tumour environment is a mechanistic feature in 
patients with clinical response to anti-PD1 therapy, but not in patients previously 
treated with ipilimumab (anti-CTLA4). Pre-exposure to anti-CTLA4 therapy may 
reduce the impact of anti-PD1 therapy on the T cell activation signature, given that 
anti-CTLA4 is likely to encourage an immunologically ‘hot’ environment and enhanced 
negative feedback (Riaz et al., 2017). Whilst these data are exploratory, the data 
support investigating the utility of TCR.strong metric in monitoring patients receiving 
anti-PD1 pathway monotherapy in in future patient cohorts and cancer subtypes.  
 
In summary our study provides new insight into how TCR signal strength and its 
manipulation control the T cell activation process. Co-inhibitory receptors rapidly re-
calibrate the activation threshold of T cells, and we demonstrate how anti-PD1 but not 
anti-Lag3 immunotherapy leads to a strong TCR signal strength signature that is a 
correlate for survival of melanoma patients on anti-PD1 monotherapy. 
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Materials and Methods 
 
Mice 
Nr4a3-Tocky Tg4 IL10-GFP (Tiger) and Nr4a3-Tocky Great Smart-17A mice (Price et 
al., 2012) were generated as previously described (Jennings et al., 2020). All animal 
experiments were approved by the local animal welfare and ethical review body and 
authorised under the authority of Home Office licences P18A892E0A and PP3965017 
(held by D.B.). Animals were housed in specific pathogen-free conditions. Both male 
and female mice were used, and littermates of the same sex were randomly assigned 
to experimental groups. Nr4a3-Tocky mice are held under MTA with Dr Masahiro Ono 
(Imperial College London). Great Smart-17A mice are held under MTA with Prof 
Richard Locksley (UCSF).  
 
In vitro cultures 
Single cell suspensions of splenocytes were generated as previously described 
(Jennings et al., 2021). Splenocyte preparations were split in half, with half undergoing 
naïve CD4+ T cells isolation using MoJo magnetic bead negative selection kits 
(BioLegend), and the other half undergoing CD90+ cell depletion (BioLegend) 
according to the manufacturer’s instructions. Naïve T cells were then mixed at a ratio 
of 1:1 with CD90-depleted splenocytes and stimulated with 1 μM of acetylated [4K] 
MBP peptide Ac-ASQKRPSQR, or [4A] Ac-ASQARPSQR or [4Y] Ac-ASQYRPSQR 
(custom products from GL Biochem Shanghai) in 10% FBS (v/v) RPMI containing 1% 
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Tg4 Nr4a3-Tocky IL10-GFP (“Tiger” (Kamanaka et al., 2006)) mice were immunised 
through subcutaneous injection of [4Y] MBP peptide (doses stated in figure legends) 
in a total volume of 200 μL into the flank. For re-challenge experiments, second doses 
were administered to the contralateral flank in a volume of 200 μL. Mice were then 




For in vivo blockade experiments, in vivo grade anti-PD1 (clone 29F.1A12, BioLegend, 
rat IgG2a), in vivo grade anti-Lag3 (clone C9B7W BioLegend, rat IgG1) or hamster 
anti-CD28 (clone 37.51, kind gift from Prof. Anne Cooke, University of Cambridge) 
were administered through intraperitoneal injection 30 minutes before peptide 
rechallenge. For anti-PD1 and anti-Lag3 experiments an isotype pool control group 
was used consisting of a 1:1 ratio of rat IgG1 (clone MAC221, kind gift from Prof Anne 
Cooke, University of Cambridge) and rat IgG2a (clone MAC219, kind gift from Prof 
Anne Cooke, University of Cambridge).  
 
Flow cytometry and cell sorting 
For analysis of splenic lymphocytes, single cell suspensions were prepared as 
described above. Cells were washed once and stained in 96-well U-bottom plates 
(Corning). Analysis was performed on a BD LSR Fortessa X-20 instrument. The blue 
form of the Timer protein was detected in the blue (450/40 nm) channel excited off the 
405 nm laser. The red form of the Timer protein was detected in the mCherry (610/20) 
channel excited off the 561 nm laser. A fixable eFluor 780-flurescent viability dye 
(eBioscience) was used for all experiments. The following directly conjugated 
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antibodies were used in these experiments: CD4 Alexa Fluor 700 (Clone RM4-4, 
BioLegend), TCRβ Alexa Fluor 700 (clone H57-597, BioLegend), CD4 BUV737 (Clone 
GK1.5, BD Biosciences) TCR Vβ8.1, 8.2 PerCP-eFluor 710 (Clone KJ16-133, 
Thermofisher), TCR Vβ8.1, 8.2 BUV395 (clone, MR5-2, BD Biosciences) CD4 
BUV395 (Clone GK1.5, BD Biosciences), CD8 BUV395 (clone 53-6.7, BD 
Biosciences), TCRβ PerCP-Cy5.5 (clone H57-597, Tonbo Biosciences), PD1 APC 
(clone 29F.1A12, BioLegend), , Tigit PE-Cy7 (clone 1G9, BioLegend), Lag3 APC or 
PE-Cy7 (clone C9B7W, BioLegend), CTLA-4 PE (clone UC10-4B9, BioLegend), OX40 
APC (clone OX-86, BioLegend), GITR PE-Cy7 (clone DTA-1, BioLegend), CD5 APC 
(clone 53-7.3, BioLegend), ICOS Alexa Fluor 700 (clone C398.4A, BioLegend). For 
cell sorting, single cell suspensions from biological replicate mice were generated and 
stained individually with distinct CD4 fluorochromes (e.g. AF700, BUV395, BUV737) 
to permit multiplexing and parallel cell sorting. Cells were sorted on a FACS Aria cell 
sorter gating on Nr4a3-Blue+Nr4a3-Red- for 4 h time point, Nr4a3-Blue+Nr4a3-Red+ 
for 12 h time point and Nr4a3-Blue-Nr4a3-Red+ for the 24 h time point. For cell sorting 
in Figure 4, cells were sorted for Nr4a3-Blue+Red+ T cells. Cells were sorted into 20% 
FBS RPMI. A small portion of sorted T cells were re-analysed on the flow cytometer 
to assess purity. Remaining cells were centrifuged for 5 minutes at 500 g before 100µL 
of extraction buffer added (Arcturus Picopure RNA kit, Thermofisher) and lysates 
frozen at -80°C.  
 
MC38 model 
MC38 colorectal cell line (kind gift from Prof. David Withers, University of Birmingham) 
was passaged in 10% FBS (v/v) RPMI containing 1% penicillin/streptomycin (Life 
Technologies). On day of experiment, MC38 cells were harvested and resuspended 
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in PBS (Sigma) at a concentration of 2.5 million/mL and 0.25 million MC38 cells 
injected sub cutaneously under the right flank of Nr4a3-Tocky Great Smart-17A mice 
in a final volume of 100 μL. Tumour size was measured using callipers. Whole tumours 
from mice were excised, weighed and then dissociated using scissors in 1.2 mL of 
digestion media containing 1 mg/mL collagenase D (Merck Life Sciences) and 0.1 
mg/mL DNase I (Merck Life Sciences) in RPMI. Samples were then incubated for 20-
25 minutes at 37°C in a thermoshaker. Digestion mixture was then passed through a 
70 μm filter (BD Biosciences) and washed with 30 mL ice cold media (10% FBS RPMI). 
Suspension was then centrifuged at 1500 rpm for 5 minutes at 4°C. Pellets were then 
re-suspended in staining media (2% FBS PBS) for labelling with fluorescently 
conjugated antibodies.  
 
RNA-seq library preparation and analysis 
RNA was extracted from lysates using the Arcturus Picopure RNA kit (Life 
technologies) according to the manufacturer’s instructions. 15-25 ng of RNA was used 
for generation of sequencing libraries using the Quantseq 3’ mRNA-seq Library 
Preparation kit (Lexogen). Briefly, library generation was commenced with oligodT 
priming containing the Illumina-specific Read 2 linker sequence. After first strand 
synthesis, RNA was degraded. Second strand synthesis was initiated by random 
priming and a DNA polymerase. Random primers contained the illumina-specific Read 
1 linker sequence. Double stranded DNA was purified from the reaction using 
magnetic beads and libraries amplified and sequences required for cluster generation 
and sample indexes were introduced. Libraries were normalised and pooled at a 
concentration of 4 nM for sequencing. Libraries were sequenced using the NextSeq 
500 using a Mid 150v2.5 flow cell. Cluster generation and sequencing was then 
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performed and FASTQ files generated. FASTQ files were then downloaded from the 
Illumina base space and uploaded to the BlueBee cloud for further analysis (Lexogen). 
FASTQ files were merged from the 4 lanes to generate final FASTQ files which were 
loaded into the BlueBee QuantSeq FWD pipeline. FASTQC files were generated and 
Bbduk v35.92 from the bbmap suite was used for trimming of low-quality tails, 
poly(A)read-through and adapter contamination. STAR v2.5.2a aligner was used for 
alignment of reads to the mouse GRCm38 (mm10) genome. HTSeq-count v0.6.0 was 
used to generate read counts for mRNA species and mapping statistics. Raw read 
counts in the .txt format were used for further analysis using DESeq2 (Love et al., 
2014) in R version 4.0.0. A DESeq dataset was created from a matrix of raw read 
count data. Data were filtered to remove genes with fewer than 10 reads across all 
samples. Log2 fold change estimates were generated using the DESeq algorithm and 
shrinkage using the ashr algorithm (Stephens, 2017) to estimate log2 fold changes. 
Principal component analysis identified one replicate batch in the effects of checkpoint 
blockade (Figure 4) to be an outlier and these three samples (which had been sorted 
and processed as a batch) were not included in further analysis. Differentially 
expressed genes (DEGs) were selected based on an adjusted p value of <0.05, which 
was obtained using the Benjamini and Hochberg method for correcting Wald test p 
values. Normalised read counts were transformed using the regularised log (rlog) 
transformation. Heatmap analysis was performed on the rlog transformed data using 
the R package gplots. For KEGG pathway analysis clusterProfiler (Yu et al., 2012), 
DOSE (Yu et al., 2015), org.Mm.eg.db, and biomaRt (Durinck et al., 2009) packages 
were used. 
 
Analysis of human nivolumab and MC38 anti-PDL1 datasets 
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Genes upregulated in human melanoma patients receiving nivolumab compared to 
pre-therapy samples were stratified into two groups as in GEO: GSE 91061 (Riaz et 
al., 2017). On therapy group (OT, n=76) consisted of genes upregulated compared to 
pre-therapy in patients regardless of clinical responses. Responder genes (Res, 
n=501) were those upregulated in patients showing clinical response to treatment 
compared to pre-therapy. For this analysis a logfold change >0.5 and adjusted p 
value<0.1 was set. The R package VennDiagram was used for analysis of overlapping 
genes between the genes in the OT, Res and genes identified in this study 
upregulated at 4 h in 80 μg vs 0.8 μg immunised mice (4hr, n=337) or genes 
upregulated 4 h after re-challenge in the presence of anti-PD1 in vivo (PD1, n=51).  
 
For analysis of gene expression in response to 0.5 mg anti-PDL1 (clone 10F.9G2) 
therapy compared to IgG2b control in mice inoculated with 0.5 million MC38 cells, raw 
count expression data was kindly provided by Dr Mirjana Efremova (Efremova et al., 
2018) from GEO: GSE93018. Differentially expressed genes (DEG) were identified 
using DESeq2 as described above. For this analysis genes were considered DEG with 
a fold change >1.5 and an adjusted p value<0.05. Normalised read counts were 
transformed using the regularised log (rlog) transformation. Heatmap analysis was 
performed on the rlog transformed data using the R package gplots. 
 
Generation and implementation of TCR.strong metric 
FPKM for TNFRSF4, ICOS, IRF8, TNIP3 and STAT4 were extracted for nivolumab 
patients from supplementary files appended to GEO: GSE 91061 (Riaz et al., 2017). 
FPKM were converted to TPM as described (Pachter, 2011) through dividing each 
gene level FPKM (offset by 0.01 to deal with 0 counts) by the sum of all FPKM in that 
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sample. This figure was then multiplied by 1e6. The geometric mean of the TPM for 
TNFRSF4, ICOS, IRF8, TNIP3 and STAT4 was then calculated, and this value 
constituted the TCR.strong metric for each patient (Supplementary Table 5). Patient 
responses were characterised as: complete remission (CR), partial remission (PR), 
stable disease (SD) or progressive disease (PD) as per (Riaz et al., 2017). Responder 
groups consisted of CR, PR and SD for analyses. Non-responders were classified as 
PD patients. Patients with missing disease outcomes or non-evaluated (NE) statuses 
from supplementary data in (Riaz et al., 2017) were excluded from responder analysis 
in Figure 6B-E. 
 
Quantification and statistical analysis 
Statistical analysis was performed on Prism 8 or 9 (GraphPad) software. For 
comparison of more than two means over time, a two-way ANOVA with Tukey’s or 
Sidak’s multiple comparison’s test was used. For comparison of Kaplan Meier survival 
curves a Log-rank (Mantel-Cox) test was used. For a comparison of more than two 
means, a one-way ANOVA with Tukey’s multiple comparisons test was used. Variance 
is reported as mean ±SEM unless otherwise stated; data points typically represent 
individual mice. Normalised Nr4a3-Timer Blue, Nr4a3-Timer Red, active TCR 
signalling and mean Timer angles were generated as previously described using 
custom algorithms (Bending et al., 2018b). Flow cytometry data were analysed using 
FlowJo software (BD Biosciences). *p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001. 
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Figure 1: Antigen dose drives digital Nr4a3 activation at the single cell level but 
graded responses at population and phenotypic levels 
(A) Schematic detailing the Tg4 Nr4a3-Tocky IL10-GFP system. (B) Tg4 Nr4a3-Tocky 
IL10-GFP mice were immunised s.c. with 0.8, 8 or 80 μg of [4Y] MBP peptide and 
splenic CD4+ T cell responses analysed for Nr4a3-Timer Red vs. Nr4a3-Timer Blue 
expression in live CD4+ Tg4 T cells at the indicated time points. (C) Summary data of 
the % of CD4+ Tg4 T cells exhibiting active TCR signalling (% Nr4a3-Blue+) or (D) 
mean Nr4a3-Timer Angle at the indicated time points in 0.8 μg (white) 8 μg (black) or 
80 ug (red) immunised mice. Bars represent mean±SEM. Statistical analysis by two-
way Anova with Tukey’s multiple comparisons test. Significant differences (p<0.05) 
between 80 μg and 0.8 μg (*), 80 μg and 8 μg (#) or 8 μg and 0.8 μg (!). (E) Tg4 Nr4a3-
Tocky IL10-GFP mice were immunised s.c. with 0.8, 8 or 80 μg of [4Y] MBP peptide 
and splenic CD4+ T cell responses analysed for CD4 vs IL10-GFP in Nr4a3-Timer+ T 
cells at 24 h post immunisation. (F) Summary data of IL10-GFP expressers (% of 
CD4+) in the three experimental groups. N=4, bars represent mean ±SEM, statistical 
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Figure 2: CD4+ T cells rapidly discriminate stimulation strength through 
transcriptionally distinct and time-dependent activation profiles 
(A) Tg4 Nr4a3-Tocky IL10-GFP mice were immunised s.c. with 0.8 or 80 μg of [4Y] 
MBP peptide and splenic CD4+ T cell responses analysed for Nr4a3-Timer Red vs. 
Nr4a3-Timer Blue expression in live CD4+ Tg4 T cells at the indicated time points (top 
panel before sorting and bottom panel after cell sorting). (B) RNA was extracted from 
the sorted populations and 3’ mRNA sequencing performed. Principal component 
analysis of the normalised expression data identifies 7 clusters containing n=3 
biological replicates. (C) Differentially expressed genes (DEGs) identified using 
DESeq2 (2-fold change, adjusted p value<0.05) between 80 μg and 0.8 μg stimulated 
T cells at indicated time points. Up DEG are in red and down DEG in blue. (D) Venn 
diagram analysis of up and down DEG at 4-,12- and 24 h time points. KEGG pathway 
analysis of DEG between 80 μg and 0.8 μg at 4 h (E) or 12 h (F) time points. (G) Z-
score heatmap analysis of log2 transformed and normalised counts of transcripts 
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Figure 3: Nr4a3 activation threshold is calibrated by dose dependent negative 
feedback 
(A)  Heatmap analysis comparing key inhibitory receptors and their relationships to 
Nr4a receptor expression from Figure 2G. (B) Diagram illustrating experimental setup 
and interpretation for part (C). (C) Tg4 Nr4a3-Tocky IL10-GFP mice were immunised 
s.c. with 0, 8 or 80 μg of [4Y] MBP. 24 h later mice were randomised to receive either 
8 or 80 μg [4Y] MBP rechallenge before splenic CD4+ T cells were analysed for 
Normalised Nr4a3-Timer Blue vs. Normalised Nr4a3-Timer Red analysis 4 h after 
peptide rechallenge. (D) Summary data displaying the frequency of arrested (Nr4a3-
Blue-Red+) TCR signalling T cells from (C). N=3, bars represent mean ±SEM, 
statistical analysis by two-way Anova with Sidak’s multiple comparisons test. (E) 
Expression of TCRb and CD4 on CD4+ T cells 28hrs after priming with the indicated 
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Figure 4: Co-inhibitory receptors exert distinct quantitative and qualitative 
control over T cell re-activation 
(A) Diagram detailing experimental design for blockade of co-inhibitory receptors. (B) 
Tg4 Nr4a3-Tocky IL10-GFP mice were immunised s.c. with 80 μg of [4Y] MBP. 24 h 
later mice were randomised to receive either 0.5 mg isotype pool (1:1 ratio of rat IgG1 
and rat IgG2a), anti-Lag3 (clone C9B7W) or anti-PD1 (clone 29F.1A12) 30 minutes 
prior to re-challenge with 8 μg [4Y] MBP peptide. Splenic CD4+ T cells were analysed 
for Nr4a3-Timer Blue vs. Nr4a3-Timer Red analysis 4 h after peptide rechallenge. 
Summary data from (B) detailing the % Responders (% Nr4a3-Blue+Red+, C) or 
median Nr4a3-Blue within Nr4a3-Blue+Red+ CD4+ T cells (D) in isotype (n=5), anti-
Lag3 (n=6) or anti-PD1 (n=6) treated mice. Bars represent mean ±SEM, dots 
represent individual mice. Statistical analysis by one-way ANOVA with Tukey’s 
multiple comparisons test. **=p<0.01, ****=P<0.0001. (E) Tg4 Nr4a3-Tocky IL10-GFP 
mice were immunised s.c. with 80 μg of [4Y] MBP. 24 h later mice were randomised 
to receive 0.8 mg isotype pool (1:1 ratio of rat IgG1 and rat IgG2a), 0.8 mg anti-Lag3 
(clone C9B7W) or 0.8 mg anti-PD1 (clone 29F.1A12) 30 minutes prior to re-challenge 
with 8 μg [4Y] MBP peptide. Splenic CD4+ T cells expression of Nr4a3-Timer Blue vs. 
Nr4a3-Timer Red 4 h after peptide rechallenge in pre-sorted (top) and sorted (bottom) 
populations. (F) RNA was extracted from the sorted populations and 3’ mRNA 
sequencing performed. Principal component analysis of the normalised expression 
data identifies 3 clusters containing n=2 biological replicates. (G) KEGG pathway 
analysis of DEG (adjusted p value<0.05) between isotype and anti-PD1 treated 
groups. (H) Z-score heatmap analysis of log2 transformed and normalised counts 
displaying the 69 DEG (51 up, 18 down) between isotype and anti-PD1 groups, in 
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Figure 5: Strong TCR signalling signatures in tumours of anti-PDL1 treated mice  
(A) 0.25 M MC38 cells were injected s.c. into Nr4a3-Tocky Great Smart-17A mice and 
tumour weight and volume recorded at days 7, 11 and 14. Bars represent mean ±SEM, 
n=3. (B) CD8+ TIL were analysed for Nr4a3-Blue vs Red (top), PD1 vs Lag3 (middle) 
or Nr4a3-Red vs IFNg-YFP (bottom) expression at the indicated time points. Summary 
data of % CD8+ TIL for (C) Nr4a3-Blue+ (blue) or Nr4a3-Red+Blue- (red), (D) PD1+ 
(black) or Lag3+ (white), (E) IFNg-YFP+ (yellow) or %IFNg+Nr4a3-Red+ (red), n=3 bars 
represent mean±SEM. (F) Z-score heatmap analysis of log2 transformed and 
normalised counts for genes significantly upregulated (>1.5-fold and adjusted p 
value<0.05) in C57BL/6 mice injected with 0.5 M MC38 cells then treated with isotype 
or anti-PDL1 every 3 to four days before whole tumors were excised and 3’ mRNA seq 
performed (GEO: GSE93018) (Efremova et al., 2018). (G) Z-score heatmap analysis 
of log2 transformed and normalised counts for genes pre-selected from 
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Figure 6: Identification of a strong TCR signal metric that stratifies melanoma 
patient responses to nivolumab therapy 
 
(A) DEG from 4 h time point of 80 μg vs 0.8 μg [4Y] MBP peptide (4hr; Figure 2), 
Isotype versus anti-PD1 (PD1; Figure 4) were intersected with DEG from melanoma 
patients who received nivolumab therapy (Riaz et al., 2017). The DEG in these 
patients were then classified based on i) the change in expression that occurred on 
therapy regardless of response compared to pre-therapy samples (OT); and ii), DEG 
that changed compared to pre-therapy samples in those patients showing clinical 
responses (Res). For human datasets a log fold change>0.5 and adjusted p value 
<0.1 was set. Genes of interest within the sets are annotated. Full lists of genes 
upregulated in the four datasets are listed in Supplementary Table 4. (B) TCR.strong 
scores in pre-therapy samples in responder (green, ipilimumab (ipi) progressed (Prog) 
n=15, ipi naïve n=11) and non-responder (orange, ipi prog n=11, ipi naïve n=12). (C) 
TCR.strong scores in on-therapy samples in responder (green, ipi prog n=18, ipi naïve 
n=10) and non-responder (orange, ipi prog n=11, ipi naïve n=10) patients. (D) 
TCR.strong scores in ipilimumab progressed patients before and after therapy (paired 
samples indicated by lines), in non-responder (NR, n=9) or responder (R, n=15). (E) 
TCR.strong scores in ipilimumab naive patients before and after therapy in non-
responder (NR, n=9) or responder (R, n=9). Bars represent median and whiskers 
reflect 10 – 90th percentiles in (B) and (C). Dots represent individual patients and lines 
pairing of samples in (D) and (E). Statistical analysis by two-way ANOVA with Sidak’s 
multiple comparisons test. Z-score heatmap analysis of log2 transformed and 
normalised counts for TCR.strong metric genes in ipilimumab naïve (F) or progressed 
(G) patients. Orange indicates non-responder patients, green indicates responder. 
Kaplan Meier survival curves for melanoma patients in ipilimumab naïve (H, pre-





























































V) CD5, GPR65, 
GCNT1
II) TNFRSF4, IRF8, 
STAT4
IV) IL2RA, IL12RB1, 
CXCR3, IL10, IL2RB, ID2
III) IFNG, GZMB, 
GBP5, CXCL9, CCL4, 






































































































GIpi Naive Ipi Prog
**











































































Ipi Naive Ipi Prog
Pre
On





















.CC-BY 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted March 2, 2021. ; https://doi.org/10.1101/2021.03.02.431957doi: bioRxiv preprint 
 
40 
therapy TCR.strong high n=10, TCR.strong low n=15; post-therapy TCR.strong high 
n=14, TCR.strong low n=7) or ipilimumab progressed patients (I, pre-therapy 
TCR.strong high n=12, TCR.strong low n=14; post-therapy TCR.strong high n=13, 
TCR.strong low n=16), stratified by high TCR.strong score (>3.5, red) or low 
TCR.strong score (<3.5, black). Comparison of survival curves by Log Rank test. 
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Supplementary Figure and Table Legends 
Supplementary Figure 1: Modified MBP peptide variants induce potent T cell 
activation in vitro (related to Figure 1) 
Naïve CD4+ T cells from Tg4 Nr4a3-Tocky IL10-GFP mice were incubated with CD90-
depleted splenocytes in the presence of 1 μM of native [4K] MBP peptide, or [4A] or 
[4Y] variants for the times indicated before analysis of Nr4a3-Blue vs Nr4a3-Red 
expression in CD4+ Tg4 T cells. (B) Summary data showing the % Nr4a3-Blue+ in 
CD4+ T cells in the 3 peptide groups. MBP [4K] = white circles, MBP [4A] = black 
squares and MBP [4Y] = red circles. Bars represent mean±SEM, n=3. Statistical 
analysis by two-way ANOVA with Tukey’s multiple comparisons test. Significant 
differences between [4Y] and [4K] = *, [4A] and [4K] = #, or [4Y] and [4A] = !. 
 
Supplementary Figure 2: Analysis of DEGs in T cells receiving strong or weak 
TCR signalling in vivo (related to Figure 2). 
(A) Z-score heatmap analysis of log2 transformed and normalised counts for all 
unique DEG identified between 0.8 and 80 μg groups at 4, 12 or 24 h. (B) KEGG 
pathway analysis of DEG at 24 h between 0.8 μg and 80 μg [4Y] MBP immunised 
mice. (C) Z-score heatmap analysis of log2 transformed and normalised counts for 
genes that show differential expression across all 3 time points (4, 12 and 24 h) 
analysed between 0.8 μg and 80 μg immunised groups.  
 
Supplementary Figure 3: Protein expression patterns of PD1, CTLA4, Lag3 and 
TIGIT in response to different grades of TCR signal strength (related to Figure 
3) 
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(A) Tg4 Nr4a3-Tocky IL10-GFP mice were immunised s.c. with 0.8 μg, 8 μg or 80 μg 
of [4Y] MBP peptide and splenic CD4+ Nr4a3-Timer+ T cells (or gated on CD4+ PD1+ 
in (B)) analysed for PD1 (A), CTLA4 (B), Tigit (C) or Lag3 (D) expression. Dots 
represent individual mice and bars represent mean ±SEM. Statistical analysis by one-
way ANOVA with Tukey’s multiple comparisons test. 
 
Supplementary Figure 4: Effects of CD28, Lag3 and PD1 pathways on T cell re-
activation in vivo (related to Figure 4) 
(A) Tg4 Nr4a3-Tocky IL10-GFP mice were immunised s.c. with 80 μg of [4Y] MBP. 24 
h later mice were randomised to receive either PBS or agonistic anti-CD28 30 minutes 
prior to re-challenge with 8 μg [4Y] MBP peptide. Splenic CD4+ T cells were analysed 
for Nr4a3-Timer Blue vs. Nr4a3-Timer Red analysis 4 h after peptide rechallenge. (B) 
Summary data of (A), control n=4, anti-CD28 n=3. (C&D) Tg4 Nr4a3-Tocky IL10GFP 
mice were immunised s.c. with 80 μg of [4Y] MBP. 24 h later mice were randomised 
to receive either isotype, anti-Lag3 or anti-PD1 30 minutes prior to re-challenge with 8 
μg [4Y] MBP peptide. The frequency of responder (Nr4a3-Blue+Red+) T cells (C) or 
Nr4a3-Blue Median expression in responder (Nr4a3-Blue+Red+) T cells (D) 4 h after 
peptide rechallenge are shown. N=3, dots represent individual mice, bars represent 
mean ±SEM. Statistical analysis by one-way ANOVA with Tukey’s multiple 
comparisons test. *=p<0.05, **=p<0.01, ***=p<0.001. 
 
Supplementary Figure 5: Majority of anti-PD1 specific T cell genes are 
upregulated in T cells receiving strong TCR signal (related to Figures 2 and 4 
and 5) 
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Genes upregulated in Tg4 CD4+ T cells 4 h after receiving 80 μg vs 0.8 μg [4Y] MBP 
(Figure 2) were intersected with genes selectively upregulated at 4hrs of T cells re-
activated in the presence of anti-PD1 in vivo (Figure 4). 28 out of 51 genes were 





Supplementary Table 1: Differentially expressed genes between 80 μg vs 0.8 μg at 
4, 12 and 24 h time points (related to Figure 2) 
 
Supplementary Table 2: KEGG pathway analysis of DEGs between 80 μg and 0.8 
μg groups at 4, 12 and 24 h post immunisation (related to Figure 2) 
 
Supplementary Table 3: DEGs between anti-PD1 vs isotype treated responder T 
cells (related to Figure 4) 
 
Supplementary Table 4: Genes upregulated in melanoma patients receiving 
Nivolumab split according to those upregulated on therapy regardless of clinical 
response (OT), vs those clinically responding (Res), or upregulated in 4 h strong 
TCR (4hr, Figure 2C) or in T cells re-activating in response to anti-PD1 (PD1, Figure 
4H) (related to Figure 6). 
 
Supplementary Table 5: FPKM and TPM for TCR.strong genes, TCR.strong 
scores, and clinical information for patients analysed (related to Figure 6)  
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